Novel potential mechanisms for diabetic macular edema: Leveraging new investigational approaches

Current Diabetes Reports

Volumn 8, Issue 4, 2008, Pages 263-269

  Gardner, Thomas W ^a   Antonetti, David A ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ASTEMIZOLE; BEVACIZUMAB; CANDESARTAN; CANNABINOL; CELECOXIB; CORTICOSTEROID; DEXAMETHASONE; DICLOFENAC; DORZOLAMIDE; DOXYCYCLINE; FLUOCINOLONE; GALACTOSE; GLUCOCORTICOID; INFLIXIMAB; LATANOPROST; MECAMYLAMINE; MINOCYCLINE; NEPAFENAC; PEGAPTANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RANIBIZUMAB; RANITIDINE; RAPAMYCIN; RUBOXISTAURIN; STEROID; TRIAMCINOLONE; UNINDEXED DRUG;

BLOOD RETINA BARRIER; CATARACT; CHRONIC INFLAMMATION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DOSE COMPARISON; DRUG TARGETING; GLAUCOMA; GLIA CELL; HUMAN; INSULIN RESISTANCE; LASER COAGULATION; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHOTORECEPTOR; PIGMENT EPITHELIUM; RETINA FLUORESCEIN ANGIOGRAPHY; REVIEW; TIGHT JUNCTION; VASCULAR ENDOTHELIUM; VITRECTOMY; ANIMAL; DISEASE MODEL; DRUG EFFECT; PATHOLOGY; PATHOPHYSIOLOGY; RETINA MACULA EDEMA;

ANIMALS; BLOOD-RETINAL BARRIER; DIABETES COMPLICATIONS; DISEASE MODELS, ANIMAL; HUMANS; MACULAR EDEMA;

EID: 52649142151     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0047-5     Document Type: Review

References (65)

1. Erickson KK, Sundstrom JM, Antonetti DA: Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 2007, 10:103-117.
2. Barber AJ, Antonetti DA: Mapping the blood vessels with paracellular permeability in the retinas of diabetic rats. Invest Ophthalmol Vis Sci 2003, 44:5410-5416.
3. Nitta T, Hata M, Gotoh S, et al.: Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 2003, 161:653-660.
4. Phillips BE, Cancel LM, Tarbell JM, Antonetti DA: Occludin regulates permeability under hydrostatic pressure and cell division in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2008 Feb 8 (Epub ahead of print).
5. Maines LW, Antonetti DA, Wolpert EB, Smith CD: Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazepine by bovine retinal endothelial cells. Neuropharmacology 2005, 49:610-617.
6. Stewart PA, Wiley MJ: Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: a study using quail-chick transplantation chimeras. Dev Biol 1981, 84:183-192.
7. Felinski EA, Cox AE, Phillips BE, Antonetti DA: Glucocorticoids induce transactivation of tight junction genes occludin and claudin 5 in retinal endothelial cells via a novel cis-element. Exp Eye Res 2008, 86:867-878.
8. Masland RH: The fundamental plan of the retina. Nat Neurosci 2001, 4:877-886.
9. Johnson MA, Lutty GA, McLeod DS, et al.: Ocular structure and function in an aged monkey with spontaneous diabetes mellitus. Exp Eye Res 2005, 80:37-42.
10. Gariano RF, Gardner TW: Retinal angiogenesis in development and disease. Nature 2005, 438:960-966.
11. Scott IU, Edwards AR, Beck RW, et al.: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007, 114:1860-1867.
12. Zacchigna. S, Ruiz de Almodovar C, Carmeliet P: Similarities between angiogenesis and neural development: what small animal models can tell us. Curr Top Dev Biol 2008, 80:1-55.
13. Gardner TW, Antonetti DA, Barber AJ, et al.: Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002, 47(Suppl 2):S253-S262.
14. Karalliedde J, Buckingham RE: Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf 2007, 30:741-753.
15. Sander B, Thornit DN, Colmorn L, et al.: Progression of diabetic macular edema: correlation with blood retinal barrier permeability, retinal thickness, and retinal vessel diameter. Invest Ophthalmol Vis Sci 2007, 48:3983-3987.
16. Soliman W, Sander B, Hasler PW, Larsen M: Correlation between intraretinal changes in diabetic macular oedema seen in fluorescein angiography and optical coherence tomography. Acta Ophthalmol 2008, 86:34-39.
17. Antonetti DA, Barber AJ, Bronson SK, et al.: Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006, 55:2401-2411.
18. Diabetic Retinopathy Clinical Research Network; Browning DJ, Glassman AR, Aiello LP, et al.: Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007, 114:525-536.
19. Writing Committee for the Diabetic Retinopathy Clinical Research Network; Fong DS, Strauber SF, Aiello LP, et al.: Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007, 125:469-480.
20. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 2005, 115:1111-1119.
21. Dana GW: Type of diabetes mellitus associated with diabetic retinitis. AMA Arch Ophthalmol 1953, 50:123-124.
22. Diabetes Prevention Program Research Group: The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007, 24:137-144.
23. Meleth AD, Agron E, Chan CC, et al.: Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 2005, 46:4295-4301.
24. El-Remessy AB, Al-Shabrawey M, Khalifa Y, et al.: Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 2006, 168:235-244.
25. Al-Shabrawey M, Rojas M, Sanders T, et al.: Role of NADPH oxidase in retinal vascular inflammation. Invest Ophthalmol Vis Sci 2008 Mar 31 (Epub ahead of print).
26. Reiter CEN, Wu X, Sandirasegarane L, et al.: Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes 2006, 55:1148-1156.
27. Seki M, Tanaka T, Nawa H, et al.: Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 2004, 53:2412-2419.
28. Storkebaum E, Carmeliet P: VEGF: a critical player in neurodegeneration. J Clin Invest 2004, 113:14-18.
29. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998, 105:1801-1815.
30. Mohamed Q, Gillies MC, Wong TY: Management of diabetic retinopathy: a systematic review. JAMA 2007, 298:902-916.
31. PKC-DMES Study Group: Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007, 125:318-324.
32. Gillies MC, Sutter FK, Simpson JM, et al.: Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006, 113:1533-1538.
33. Csaky KG, Richman EA, Ferris FL 3rd: Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci 2008, 49:479-489.
34. Joussen AM, Murata T, Tsujikawa A, et al.: Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001, 158:147-152.
35. Skondra D, Noda K, Almulki L, et al.: Characterization of azurocidin as a permeability factor in the retina: involvement in VEGF-induced and early diabetic blood-retinal barrier breakdown. Invest Ophthalmol Vis Sci 2008, 49:726-731.
36. Antonetti DA, Barber AJ, Khin S, et al.: Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 1998, 47:1953-1959.
37. Navaratna D, McGuire PG, Menicucci G, Das A: Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 2007, 56:2380-2387.
38. Aiello LP: The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Ophthalmol 2002, 47(Suppl 2):S263-S269.
39. Antonetti DA, Wolpert EB, Demaio L, et al.: Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 2002, 80:667-677.
40. Ishii H, Jirousek MR, Koya D, et al.: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996, 272:728-731.
41. Kuppermann BD, Blumenkranz MS, Haller JA, et al.: Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007, 125:309-317.
42. Aiello LP, Davis MD, Girach A, et al.: Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006, 113:2221-2230.
43. Giebel SJ, Menicucci G, McGuire PG, Das A: Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 2005, 85:597-607.
44. Behzadian MA, Wang XL, Windsor LJ, et al.: TGF-beta increases retinal endothelial cell permeability by increasing MMP-9: possible role of glial cells in endothelial barrier function. Invest Ophthalmol Vis Sci 2001, 42:853-859.
45. Rungger-Brandle E, Dosso AA, Leuenberger PM: Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci 2000, 41:1971-1980.
46. Wilkinson-Berka JL, Fletcher EL: Angiotensin and bradykinin: targets for the treatment of vascular and neuro-glial pathology in diabetic retinopathy. Curr Pharm Des 2004, 10:3313-3330.
47. Hata Y, Clermont A, Yamauchi T, et al.: Retinal expression, regulation, and functional bioactivity of prostacyclin-stimulating factor. J Clin Invest 2000, 106:541-550.
48. Duh EJ, Yang HS, Haller JA, et al.: Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol 2004, 137:668-674.
49. Abu El-Asrar AM, Dralands L, Missotten L, Geboes K: Expression of antiapoptotic and proapoptotic molecules in diabetic retinas. Eye 2007, 21:238-245.
50. Ramasamy R, Vannucci SJ, Yan SS, et al.: Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005, 15:16R-28R.
51. Aiello LP, Bursell SE, Clermont A, et al.: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997, 46:1473-1480.
52. Hollis TM, Gardner TW, Vergis QJ, et al.: Antihistamines reverse blood-ocular barrier breakdown in experimental diabetes. J Diabetic Complications 1988, 2:47-49.
53. Gardner TW, Eller AW, Friberg TR, et al.: Antihistamines reduce blood-retinal barrier permeability in patients with type I (insulin-dependent) diabetes and nonproliferative diabetic retinopathy. A Pilot Study. Retina 1995, 15:134-140.
54. Krady JK, Basu A, Allen CM, et al.: Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005, 54:1559-1565.
55. Vincent JA, Mohr S: Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 2007, 56:224-230.
56. Kern TS, Miller CM, Du Y, et al.: Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 2007, 56:373-379.
57. Muranaka K, Yanagi Y, Tamaki Y, et al.: Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model. Invest Ophthalmol Vis Sci 2006, 47:4547-4552.
58. Zhang SX, Wang JJ, Gao G, et al.: Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 2006, 20:323-325.
59. Joussen AM, Poulaki V, Mitsiades N, et al.: Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002, 16:438-440.
60. Barile GR, Pachydaki SI, Tari SR, et al.: The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005, 46:2916-2924.
61. Gao BB, Clermont A, Rook S, et al.: Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 2007, 13:181-188.
62. Cunningham ET Jr, Adamis AP, Altaweel M, et al.: A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005, 112:1747-1757.
63. Gardner TW, Sander B, Larsen ML, et al.: An extension of the Early Treatment Diabetic Retinopathy Study (ETDRS) system for grading of diabetic macular edema in the Astemizole Retinopathy Trial. Curr Eye Res 2006, 31:535-547.
64. Sjolie AK, Porta M, Parving HH, et al.: The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. J Renin Angiotensin Aldosterone Syst 2005, 6:25-32.
65. Tsilimbaris MK, Panagiotoglou TD, Charisis SK, et al.: The use of intravitreal etanercept in diabetic macular oedema. Semin Ophthalmol 2007, 22:75-79.